Curr Opin Virol. 2019 Apr;35:57-62. doi: 10.1016/j.coviro.2019.04.002. Epub 2019 May 21.
Nucleoside analogues for the treatment of coronavirus infections.
Abstract
Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV
drug development has long been challenged by the activity of a 3' to 5'
proofreading exoribonuclease unique to CoVs. Recently, a promising
nucleoside analogue with broad-spectrum activity against CoVs has been
identified. This review will discuss progress made in the development of
antiviral nucleoside and nucleotide analogues targeting viral RNA
synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.
Copyright © 2019. Published by Elsevier B.V.
- PMID:
- 31125806
- DOI:
- 10.1016/j.coviro.2019.04.002
Inga kommentarer:
Skicka en kommentar